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Abstract
Medulloblastoma is the most common pediatric malignant brain tumor, arising from aberrant cerebellar precursors’
development, a process mainly controlled by Hedgehog (Hh) signaling pathway. Histone deacetylase HDAC1 has
been recently shown to modulate Hh signaling, deacetylating its effectors Gli1/2 and enhancing their transcriptional
activity. Therefore, HDAC may represent a potential therapeutic target for Hh-dependent tumors, but still little infor-
mation is available on the physiological mechanisms of HDAC regulation. The putative tumor suppressor RENKCTD11
acts through ubiquitination-dependent degradation of HDAC1, thereby affecting Hh activity and medulloblastoma
growth. We identify and characterize here two RENKCTD11 homologues, defining a new family of proteins named
KCASH, as “KCTD containing, Cullin3 adaptor, suppressor of Hedgehog.” Indeed, the novel genes (KCASH2KCTD21
and KCASH3KCTD6) share with RENKCTD11 a number of features, such as a BTB domain required for the formation of
a Cullin3 ubiquitin ligase complex and HDAC1 ubiquitination and degradation capability, suppressing the acetylation-
dependent Hh/Gli signaling. Expression of KCASH2 and -3 is observed in cerebellum, whereas epigenetic silencing
and allelic deletion are observed in human medulloblastoma. Rescuing KCASHs expression reduces the Hedgehog-
dependent medulloblastoma growth, suggesting that loss of members of this novel family of native HDAC inhibitors
is crucial in sustaining Hh pathway–mediated tumorigenesis. Accordingly, they might represent a promising class of
endogenous “agents” through which this pathway may be targeted.
Neoplasia (2011) 13, 374–385
Abbreviations: Hh, Hedgehog; KCASH, KCTD containing, Cullin3 adaptor, suppressor of Hedgehog; HDAC, histone deacetylase; Cul, Cullin
Address all correspondence to: Alberto Gulino, MD, PhD, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
E-mail: alberto.gulino@uniroma1.it
1This work was supported, in part, by Associazione Italiana Ricerca Cancro, Telethon grant GGP07118, MIUR FIRB and PRIN projects, Ministry of Health, Fondazione Roma,
Fondazione Mariani, EU Healing grant, Italian Institute of Technology, and Agenzia Spaziale Italiana. M.P. and M.M. are supported by fellowships from the Pasteur Institute,
Cenci Bolognetti Foundation. The authors declare that they have no conflict of interest.
2This article refers to supplementary materials, which are designated by Figures W1 to W3 and are available online at www.neoplasia.com.
3These authors contributed equally to this work.
Received 23 November 2010; Revised 27 January 2011; Accepted 27 January 2011
Copyright © 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00
DOI 10.1593/neo.101630
www.neoplasia.com
Volume 13 Number 4 April 2011 pp. 374–385 374
Introduction
Medulloblastoma (MB) is the most common malignant brain tumor in
children, which accounts for 10% to 20% of primary central nervous
system (CNS) neoplasms, and requires aggressive surgery and com-
bined radiation and chemotherapeutic treatments [1]. Although the
prognosis has improved in the last few years, still a large number of
MB patients undergo tumor relapse or serious neurologic and cognitive
adverse effects. These facts highlight the need for an improved knowl-
edge of the complex molecular biology of MB to develop new and more
efficient therapeutic strategies [2–4]. MB arises from defects in control
of cerebellar development and differentiation and, in particular, from
cerebellar granule cell precursors that maintain their proliferating and
undifferentiated state after the maturation age [5,6]. Granule cell pre-
cursor proliferation and differentiation is a process mainly controlled
by the level of Hedgehog (Hh) pathway activity [7–9], and Hh dys-
regulation is now recognized as a leading cause of MB tumorigenesis
[5,7,10–12]. As a consequence, the mechanism that regulates Hh path-
way activity is now considered among the most important therapeutic
targets for MB treatment [13–16].
Histone deacetylases (HDACs) play a pivotal role in developmental
processes and tumorigenesis, regulating gene expression through the
modulation of the acetylation status of histones and nonhistonic proteins
[17]. HDACs have been recently involved in Hh modulation [18]. In
particular, HDAC1 has been recently demonstrated to deacetylate the
transcription factors Gli1 and Gli2 (the main Hh pathway effectors)
and, through this mechanism, enhance their transcriptional activity [18].
Because an increased HDAC activity is a common finding in cancer
cells, HDACs have been proposed as effective targets for cancer therapy
[17]. Several chemical classes of HDAC inhibitors (HDACi) have
been identified and are currently being tested for human cancer therapy
(reviewed in Lane and Chabner [19]). Nevertheless, scant information
is still available on the mechanism of the physiological regulation of
HDAC proteins.
Indeed, although a few endogenous cell signals have been described
to regulate HDAC function through posttranslational modifications
(e.g., phosphorylation, sumoylation, acetylation, and ubiquitination),
the role of these regulatory events in cancer is not yet defined [20–
22] (reviewed in Di Marcotullio et al. [23]).
Growing evidence indicates the relevance of ubiquitination-dependent
control of HDACs. Ubiquitination is a posttranslational modification
that involves the action of different enzymes (E1, E2, E3) and ends
with the transfer of ubiquitin to substrate proteins, which are then
targeted to the proteasome and degraded [24]. The oncosuppressors
RENKCTD11 and Chfr downregulate HDAC1 by inducing its ubiquitin-
dependent degradation [18,25]. Importantly, the frequent deletion or
silencing of RENKCTD11 and Chfr observed in medulloblastoma (MB)
and other cancer types highlights the relevance of physiological mecha-
nisms that, by repressing HDAC function, may prevent tumorigenesis.
We previously reported that RENKCTD11 plays an important role
during cerebellar granule differentiation [26] and its loss, associated to
chromosome 17p deletion, is linked toMB formation [27]. RENKCTD11
was recently identified as a part of Cullin3 (Cul3) E3 ubiquitin ligase
complex, which inhibits HDAC1 function by inducing its ubiquitina-
tion and subsequent degradation [18]. HDAC1 suppression is in turn
responsible for the inhibitory role of RENKCTD11 on Hh signaling [18].
While searching for additional Hh suppressors in human cancers, we
have cloned and characterized two homologues of the RENKCTD11.
This finding prompted us to hypothesize that RENKCTD11-mediated
control of HDAC1 could represent a model shared by additional tumor
suppressors, which may act in a concerted fashion. The two new genes
in fact allowed us to define a new family of proteins that we named
KCASH, as “KCTD containing, Cullin3 adaptor, suppressor of Hedge-
hog.” The two genes KCASH2KCTD21 and KCASH3KCTD6 share a
number of features, such as high homology and a BTB domain respon-
sible for oligomerization and interaction with Cul3, specific expression
in brain and cerebellum, suppressor activity on acetylation-dependent
Hh/Gli signaling through ubiquitination and degradation of HDAC1,
genetic loss or silencing in human primary MBs, and growth-inhibitory
activity on MB cells.
The results presented here indicate that the three KCASH genes
belong to a subfamily of KCTD containing proteins. The discovery
of such a novel family suggests that these negative regulators of Hh/
Gli signaling act in concert as native HDAC inhibitors and that their
genetic or epigenetic defects are crucial in sustaining Hh/Gli and
HDAC-mediated tumorigenesis. Accordingly, they might represent a
promising class of endogenous “agents” through which this oncogenic
addiction pathway may be targeted.
Materials and Methods
Human and Mouse Tissue Samples
Human primary MB specimens were collected during surgical re-
section with the approval of institutional review board as previously
described [28]. RNA of normal human cerebellum (nine adult sam-
ples from 22- to 82-year-old subjects and four fetal samples from 22
to 37 weeks) were purchased from Biocat (Heidelberg, Germany),
Ambion (Applied Biosystems, Foster City, CA), and BD Biosciences
(San Jose, CA). Mouse normal cerebella and tissues were obtained from
C57Bl/6 mice (Charles River, Calco, Italy).
Cell Cultures, Transfection, Treatments, and Luciferase Assay
HEK293T cells were cultured in Dulbecco modified Eagle medium
(Gibco, Carlsbad, CA) plus 10% FBS, Daoy and D283 MB cells were
cultured in minimum essential medium (Gibco, Carlsbad, CA), sup-
plemented with 10 and 20% FBS, respectively, 1% sodium pyruvate,
1% nonessential amino acid solution, 1% L-glutamine, and penicillin/
streptomycin. Transfections were performed with Lipofectamine 2000
or Plus (Invitrogen, Carlsbad, CA).
KCASH2 small interfering RNA (siRNA) was performed using
SMART pool siRNA duplexes (30 nM; M-026714-01, Dharmacon)
transfected with HiPerFect Reagent (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. KCASH1 siRNA knockdown
was performed with pools of siRNA duplexes (100 nM) (Ambion; cat.
4392420; ID s44957 and s44959) transfectedwith Lipofectamine 2000.
Retinoic acid (2.5 μM; all-trans-retinoic acid; Sigma-Aldrich, St
Louis, MO), epidermal growth factor (Sigma-Aldrich; 20 ng/ml),
and nerve growth factor (Upstate, Lake Placid, NY; 100 ng/ml) treat-
ments were performed from 6 to 48 hours on D283 MB cells. Lucif-
erase and Renilla activity were assayed with a dual-luciferase assay
system (Promega, Madison, WI). Results are expressed as luciferase/
Renilla ratios and represent the means ± SD of at least three experi-
ments, each performed in triplicate.
Plasmids and Mutagenesis
The following plasmids were provided by other laboratories: 12×
Gli-Luc (R. Tofgard, Karolinska Institutet, Sweden), pBJ5-HDAC1
(S. Shereiber, Harvard University, MA), pCMV-HDAC1 (P.L. Puri,
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The Burnham Institute, CA), pcDNACul1-HA, Cul2-myc, Cul3-myc
(M. Pagano,NewYorkUniversity School ofMedicine,NY). Polymerase
chain reaction (PCR)–amplified complementary DNA (cDNA) of
human Gli1, KCASH1, KCASH2, KCASH3, BTB-KCASH2, ΔBTB-
KCASH2, and mutated forms were tagged (HA, Flag, or Myc tag) and
cloned in the pCXN mammalian expression vector. Single or multiple
residues were mutated using the QuickChange site–directed or multisite
mutagenesis kits (Stratagene, La Jolla, CA).
RNA Isolation and Quantitative Real-time PCR
Total RNA from tissue samples and cells was extracted using TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions, and
cDNA synthesis was performed using the SuperScript II First-Strand
Synthesis kit (Invitrogen). Quantitative real-time PCR analysis of Gli1,
KCTD11, KCASH2, KCASH3, β-actin, GAPDH, and HPRTmes-
senger RNA (mRNA) was performed on cDNA using TaqMan gene
expression assays according to the manufacturer’s instructions (Applied
Biosystems) and using the ABI Prism 7900HT (Applied Biosystems)
as previously described [29]. The designed assays on demand were
the following: human KCASH2 forward 5′-gcgagggcaggaggactact-3′,
human KCASH2 reverse 5′-cgccagtgaggttgtatagagagctt-3′, human
KCASH2 probe 6-FAM-caacccagtctcctgc-MGB; mouse KCASH2
forward 5′-gagcgagggcaggagtatttc-3′, mouse KCASH2 reverse 5′-
cccccaacattcagtgtaatgg-3′, mouse KCASH2 probe 6-FAM-cacccagcctcc-
tac-MGB. Each amplification reaction was performed in triplicate, and
the average of the three threshold cycles was used to calculate the amount
of transcripts in the sample (SDS software; ABI). mRNA quantification
was expressed, in arbitrary units, as the ratio of the sample quantity to the
calibrator or to the mean values of control samples. All values were nor-
malized to three endogenous controls, GAPDH, β-actin, and HPRT.
Western Blot Analysis, Immunoprecipitation, and
Ubiquitination Assay
Cells were lysed with buffer containing: 50 mM Tris-HCl (pH 7.6),
deoxycholic acid sodium salt 1%, 150 mM NaCl, 1% NP40, 5 mM
EDTA, 100 mM NaF, and protease inhibitors. Total protein extracts
were then separated on a denaturing SDS-PAGE gel and evaluated
by Western blot assay using the antibodies listed below.
For coimmunoprecipitation, lysates were incubated with agarose-
conjugated Flag M2 beads (Sigma) for 2 hours at 4°C. Control sample
antibody was saturated with peptide anti-Flag (Sigma). Beads were
washed extensively with lysis buffer, and the complexes were evaluated
by Western blot analysis. In vivo ubiquitination assays were performed
as previously described [30]; briefly, cells were lysed with denaturing
RIPA buffer to disrupt protein-protein interactions and then immuno-
precipitated with the indicated antibodies.
Antibody sources were as follows: goat polyclonal antibody against
actin (Santa Cruz Biotechnology, Santa Cruz, CA), secondary antibody
anti–mouse/rabbit/goat IgG conjugated with HRP (Santa Cruz), and
mouse monoclonal antibody against HA and against Myc (Santa Cruz)
and against Flag (M2, Sigma). Anti-KCASH2 antibodies have been
developed in-house or custom-made (Biosense, Milan, Italy).
Gene Copy Number Assay
KCASH2 and KCASH3 gene copy numbers were measured by quan-
titative real-time PCR. DNA from MB specimens and paired blood
cells were isolated by overnight treatment with proteinase K at 50°C
followed by phenol-chloroform extraction and precipitation with etha-
nol. PCRs were performed using TaqMan copy number assay according
to the manufacturer’s instructions (Applied Biosystems) on an ABI
Prism 7900 Sequence Detection System (Applied Biosystems) accord-
ing to the standard thermal profile (2 minutes at 50°C, 10 minutes
at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute
at 60°C). For the relative quantification of allele copy number, two
different methods have been used: the standard curve method and
the comparative C t method, in tumor DNA sample relative to the nor-
mal DNA from the same patient (calibrator) and relative to RNaseP
as endogenous control.
Cell Proliferation and Colony Assays
Cell proliferation was evaluated by BrdU incorporation (4-hour
pulse). Briefly, after the BrdU pulse, cells were fixed with 4% para-
formaldehyde and permeabilized with 0.1% Triton X-100, and BrdU
detection (Roche, Basel, Switzerland) was performed according to the
manufacturer’s instructions. Nuclei were counterstained with Hoechst
reagent. At least 500 nuclei were counted in triplicate, and the number
of BrdU-positive nuclei was recorded. For colony formation assays, 1 ×
104 transfected Daoy MB cells were plated in 10-cm-diameter dishes,
and after 2 weeks of neomycine selection, cell colonies were counted
after staining in 20% methanol and crystal violet. In all experiments
in which additive effects of KCASH1 and -2 or -3 were evaluated,
the amount of total transfected plasmid was maintained the same,
(i.e., 5 μg in the case of a single transfected plasmid, 2.5 μg of each
plasmid, in the case of two transfected plasmids).
Results
Identification of KCASH Family Members
The search for protein homologues to RENKCTD11 on the public
databases and subsequent analysis on the Ensemble genome browser
[31] resulted in the identification of twoORFcoding for potassiumchannel
tetramerization domain containing 21 (KCTD21; NM_001029859.1)
and potassium channel tetramerization domain containing 6 (KCTD6;
NM_001128214.1) putative proteins (see Figures 1A andW1A). Both
transcripts are encoded by biexonic genes mapping to human chromo-
somes 11q14.1 (KCTD21) and 3p14.3 (KCTD6), although the CDS
are coded only by the second exon.
Similar to RENKCTD11, KCTD21 and KCTD6 contain a BTB do-
main sharing a high homology (58% [64/109 aa] and 54% [59/109 aa],
respectively) versus the RENKCTD11 BTB motif, whereas the whole
sequences present a 42% (111/260 aa) and 32% (77/237 aa) of ho-
mology, respectively (see Figure W1A).
These genes are conserved throughout most vertebrates (RENKCTD11
andKCTD6 in euteleostoma,KCTD21 in amniota) and have similarities
to a gene coding for a KCTD-containing protein present in basal chor-
dates such as the sea squirtCiona intestinalis (ENSCSAVG00000010257,
not shown). The phylogenetic tree seems to indicate that the KCTD6
gene branched earlier in the evolution than both RENKCTD11 and
KCTD21 (Figure 1A).
The high homology within the three KCTD-containing proteins
suggests that they belong to a gene family that shares common struc-
tural and functional features and may play similar biologic roles (see
also below). For this reason and based on the functional features of
RENKCTD11 [18], we have named this family KCASH (KCTD contain-
ing, Cullin3 adaptor, suppressor of Hedgehog). KCTD21 is therefore
referred as KCASH2 and KCTD6 as KCASH3, whereas RENKCTD11
is renamed KCASH1.
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Analysis of the expression of KCASH2 and KCASH3 in different
mouse tissues indicated that both are highly expressed in cerebellum
and brain, two organs in which also KCASH1 has been described to
play a critical role in development and differentiation (Figure 1B and
Argenti et al. [26]).
Accordingly, analysis of KCASH2 and KCASH3 mRNA expression
levels in human cerebellar samples during development indicates an
increase in the expression of the two genes in adult differentiated
cerebellum compared with fetal cerebellum (Figure 1, C and D). To
determine the expression of KCASH2- and KCASH3-encoded protein,
we generated (and validate by siRNA) antibodies against KCASH2,
which were able to recognize the endogenous 30-kDa protein (Fig-
ureW1B). Attempts to generate antibodies for KCASH3 have not been
successful so far, probably because of the low immunogenicity of the
protein. Analysis of KCASH2 protein levels in mouse adult and P7
cerebellar samples confirmed the modulation of the mRNA observed
during development in human (Figure 1E).
KCASH Family Members Form Homo-oligomeric and
Hetero-oligomeric Complexes
The BTB domain has been described to mediate the formation of
oligomerization complexes [32]. Here we demonstrate that KCASH2
and KCASH3 are able to form homo-oligomers, as evaluated by co-
immunoprecipitating KCASH2 or KCASH3 HA- and Flag-tagged pro-
teins (Figure 2A). Similar results were observed for KCASH1REN/KCTD11
(Figure 2A and Correale et al. [33]). The oligomerization domain was
confirmed to be located in the BTB motif because HA-KCASH1 and
Flag-ΔBTBKCASH1 (deleted of the BTB motif, ΔBTB1) or HA-
KCASH2 and Flag-ΔBTBKCASH2 (ΔBTB2) did not coimmuno-
precipitate (Figure 2A). Interestingly, the three family members were
able to form hetero-oligomers with each other, with the exception of
KCASH2/KCASH3 (Figure 2, B–D). The lack of interaction between
KCASH2 and KCASH3 confirms the increased divergence of these
two family members (Figure 2C).
Thus, the newly discovered KCASH family members share a num-
ber of features, such as high homology of both the BTB domain and
whole sequence, specific expression in brain and cerebellum, and the
ability to form hetero-oligomer and homo-oligomer complexes, sug-
gesting that these proteins might also share some functional properties.
KCASH2 and KCASH3 Share with KCASH1 the Ability
to Bind to Cullin3
KCASH1REN/KCTD11 has been recently identified as a Cullin3
(Cul3) E3 ubiquitin ligase and has been shown to interact with Cul3
through the BTB domain and thus to form the active E3 ligase complex
[18]. To verify whether KCASH2 and KCASH3 also share this prop-
erty, we looked at the interaction of these proteins with Cullins. By
coimmunoprecipitation experiments, we observed that both KCASH3
and KCASH2 were able to interact with Cul3, but not with Cul1 and
Cul2 proteins (Figure 3, A and B), similar to what previously observed
for KCASH1 [18]. We have also identified the amino acid residues
of the Cul3 protein required for binding to KCASH2 and KCASH3.
In fact, KCASH2 and KCASH3 coimmunoprecipitation with Cul3
was abolished by mutation of tyrosines Y58, Y62, and Y125 to lysines
Figure 1. Identification of KCASH family members. (A) Phylogenetic tree of KCTD11, KCTD21, and KCTD6 (left panel) and schematic
representation of their human genetic locus (right panel). (B) KCASH2 and KCASH3 mRNA levels in adult mouse tissues evaluated by
quantitative real-time PCR. Values shown are calculated relative to values in lymph nodes. KCASH2 (C) and KCASH3 (D) mRNA expression
in fetal (n = 4) and adult (n = 9) human cerebella. Values obtained by quantitative real-time PCR. *P < .05 adult versus fetal cerebella.
(E) Western blot analysis of endogenous levels of KCASH2 protein in immature (P7) and adult mouse cerebellum.
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in the Cul3 protein (Cul3m; Figure 3, B and C ). These results con-
firmed the relevance of these residues, previously demonstrated for
the interaction with the other family member KCASH1REN/KCTD11
[18] and indicated a similar mechanism of interaction with Cul3 by
all three KCASH family members. Similar to what previously described
for KCASH1 [18], the KCASH2 protein domain critical for binding to
Cul3 is the BTB-containing region, which is sufficient for coimmuno-
precipitation with wild-type Cul3 (Figure 3C), whereas this interaction
is abolished when Cul3 is mutated (Cul3m; Figure 3C). Accordingly,
KCASH2 protein deleted of the BTB domain is not able to immuno-
precipitate Cul3 (see Flag-ΔBTB; Figure 4A).
We were also able to map the Cul3 binding region identifying three
critical residues on the BTB domain of KCASH2 (DFY; Figure W1A).
Mutation of the DFY residues (to KKK) abolished Cul3 binding (Fig-
ure 3D), confirming results observed with KCASH1 protein [18]. In-
terestingly, these DFY residues are also conserved in the KCASH3 BTB
domain (Figure W1A), supporting the critical role of this domain for
Cul3 interaction.
KCASH2 and KCASH3 Promote the Ubiquitination
of HDAC1
Binding to Cul3 and the functional properties of the KCASH1 homo-
log [18] suggest that KCASH2 and KCASH3may also promote ubiqui-
tination. Indeed, this property together with the functional role of the
BTB domain was confirmed by the ability of KCASH2 to coimmuno-
precipitate ubiquitinated proteins, whereas immunoprecipitation of
KCASH2 devoid of the BTB domain failed to do so (Figure W2A).
The most likely candidate substrate for KCASH2 and 3/Cul3 com-
plexes is HDAC1, based on the recently identified HDAC1 as a sub-
strate of the KCASH1/Cul3 complex [18]. KCASH2 was found to
bind to HDAC1 through the C-terminal region because KCASH2
protein truncated of the N-terminal BTB motif (ΔBTB) is still able
to bind to HDAC1 (Figure 4A). Interestingly, the coimmunoprecipi-
tated KCASH2/HDAC1 complex also contains Cul3 which instead is
missing in the ΔBTB/HDAC1 complex (Figure 4A). These observa-
tions suggest that KCASH2, HDAC1, and Cul3 form a trimeric com-
plex through the involvement of the Cul3 binding BTB motif.
Surprisingly, KCASH3 was instead unable to bind HDAC1 protein
in coimmunoprecipitation experiments (Figure 4B). Because KCASH3
and KCASH1 are able to heterodimerize (Figure 2D), we hypothesized
that KCASH1 may tether the HDAC1 protein into a complex with
KCASH3, in which both KCASH3 and KCASH1 contribute to Cul3
recruitment. Indeed, coimmunoprecipitation experiments performed
by overexpression of both KCASH3 and KCASH1 indicated that
KCASH3 was able to immunoprecipitate HDAC1 in the presence of
KCASH1 (Figure 4C ).
Formation of the KCASH2-Cul3-HDAC1 complex resulted in the
ubiquitination of HDAC1, whereas ΔBTB-KCASH2 was unable to
promote HDAC1 ubiquitination (Figure 4D, left panel ). Consistently,
KCASH3 also promoted the HDAC1 ubiquitination (Figure 4D, right
Figure 2. KCASH family members form homodimeric and heterodimeric complexes. (A–D) Coimmunoprecipitation experiments performed
in lysates from HEK293T cells transfected with expression vectors encoding for the indicated tagged proteins and immunoprecipitated (IP)
with anti-Flag agarose beads. As a negative control (Ctr), anti-Flag agarose beads were preblocked with Flag peptide. Immunoprecipitated
samples and a fraction of the total lysate (Total) were loaded and separated on SDS-PAGE gels. Blots were immunoblotted (IB) with anti-HA
or anti-Flag antibody as indicated. ΔBTB1 and ΔBTB2 indicate BTB-deleted KCASH1 and KCASH2, respectively. Reblots with anti-Flag anti-
body were performed to verify immunoprecipitation.
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panel ). As a consequence of such ubiquitination, both KCASH2 and
KCASH3 expression induced a decrease in the levels of HDAC1 pro-
tein, indicating that ubiquitination promotes HDAC1 proteolytic deg-
radation (Figure 4E).
KCASH2 and KCASH3 Downregulate Gli Transcriptional
Activity in an Acetylation-Dependent Way
One of the main pathways involved in cerebellar development and
differentiation is the Hh pathway. This pathway has been previously
shown to be regulated by KCASH1 that promotes the HDAC1 deg-
radation, thus increasing Gli acetylation and suppressing its tran-
scriptional function [18,26,34]. On the basis of the features shared
by KCASH2 and KCASH3 with KCASH1, we investigated whether
the two proteins were able to control Hh pathway through a similar
mechanism. Here, we demonstrated that overexpression of KCASH2
or KCASH3 significantly decreased the transcriptional activity of ectopic
Gli1 on a Gli-responsive luciferase reporter (Figure 5, A and B) and
the levels of endogenous Gli1 mRNA, as a read out of Hh signaling
(Figure 5C ; for a comparison, levels of Gli mRNA reduction by
KCASH1 expression are also shown). As expected, the KCASH2 protein
Figure 3. KCASH2 and KCASH3 share with KCASH1 the ability to bind to Cullin3 E3 ligase through the same domains. (A–D) Coimmuno-
precipitation experiments have been performed as in Figure 2, overexpressing KCASHmembers and HA orMyc-tagged Cul1-3 as indicated.
Immunoprecipitation was carried out with anti-HA or anti-Flag antibodies, and immunocomplexes were revealed with the indicated anti-
bodies. (A) KCASH2 form a complex with Cul3 but not Cul1 and Cul2. (B) KCASH3 does not bind Cul1 and Cul2 but forms a complex with
Cul3, which is abolished by mutation of Cul3 in three critical residues (Y58/62/125K, indicated as Cul3m). (C) KCASH2 BTB domain (HA-BTB)
is sufficient for Cul3 binding, and this interaction is lost by mutation of Cul3. Cells were transfected with myc-Cul3 or Myc-Cul3mut together
with HA-KCASH2 or HA-BTB as indicated. (D) KCASH2 interaction with Cul3 is abolished by specific mutations in the BTB domain. Myc-Cul3
was transfected together with Flag-KCASH2 or Flag-KCASH2KKK mutant (KCASHm), and immunoprecipitations were performed as above.
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devoid of BTB domain was not able to reduce the luciferase activity
(Figure 5A). To investigate whether KCASH2 and KCASH3 activity
was due to the acetylation of Gli1, we tested the activity of the ectopic
proteins by using an unacetylatable Gli1 mutant (Gli1K518R) [18].
K518R displayed an increased ability to activate the luciferase activity,
confirming the critical role of lysine 518 deacetylation in enhancingGli1
function. As expected, KCASH2 and KCASH3 (and KCASH1, as also
previously reported in Canettieri et al. [18]) were unable to antagonize
Figure 4. KCASH2 and KCASH3 bind to and promote HDAC1 ubiquitination and degradation. (A) KCASH2 binds to HDAC1, through its
C-terminal domain (ΔBTB domain), bringing together Cul3 and HDAC1. (B and C) KCASH3 alone does not bind efficiently to HDAC1 (B),
but the interaction with HDAC1 is mediated by binding to KCASH1 (C). Lysates from HEK293T cells cotransfected with the indicated plas-
mids were immunoprecipitated and blotted as in Figure 3. (D) KCASH2 and KCASH3 expression induces HDAC1 ubiquitination. Expression
of a KCASH2 protein devoid of the BTB domain (ΔBTB) indicates that this function is dependent on the presence of the BTB domain.
KCASH1-dependent ubiquitination is also shown for a comparison. Cell lysates from MG132 (50 μM)-treated HEK293T cells, transfected
with the indicated plasmids and HA-ubiquitin, were immunoprecipitated with anti-Flag agarose beads and immunoblotted with anti-HA to
detect conjugated HA-Ub. The blot was reprobed with an anti-Flag antibody to monitor immunoprecipitation efficiency. Bottom, KCASH1-3
and KCASH2-ΔBTB (ΔBTB) total protein levels. The amount of each transfected plasmid is 1 μg except for KCASH3 (1 and 2 μg). (E) KCASH2
and KCASH3 expression reduces HDAC1 protein levels. HEK293T cells were transfected with Flag-HDAC1 in the presence or absence of
increasing amounts (1, 2, and 4 μg) of Flag-KCASH2 or Flag-KCASH3 and cell lysates immunoblottedwith anti-Flag and anti-Actin antibodies.
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Figure 5. KCASH2 and KCASH3 downregulate Gli transcriptional function in an acetylation-dependent way. (A and B) KCASH2 and KCASH3
downregulate transcriptional Gli activity. Relative luciferase activity in HEK293T cells transfected with 12× Gli-Luc and pRL-TK Renilla (as
a normalizer) alone (ctrl) or with increasing amounts (100, 200, and 400 ng) of KCASH2 or KCASH2-ΔBTB (ΔBTB) (A) or KCASH3 (B). Data
are indicated as mean ratios with respect to pRL-TK Renilla luciferase signal. *P< .05 Gli1 versus control, **P< .05 KCASH2 or KCASH3 +
Gli1 versus Gli1. (C) Endogenous Gli1 mRNA levels evaluated by quantitative real-time PCR in HEK293T cells cotransfected with Gli1,
KCASH2, KCASH3 or KCASH1 (shown for comparison). *P < .05 Gli1 versus control, **P < .05 KCASH2 or KCASH3 + Gli1 versus Gli1.
(D, E) KCASH2 and KCASH3 downregulatory activity depends on acetylation of HDAC1. Relative luciferase activity in HEK293T cells co-
transfected with 12× Gli-Luc and pRL-TK Renilla plus Gli1, Gli1K518R, HDAC1, KCASH2, and KCASH3 expression vectors as indicated.
KCASH1 was also transfected for comparison. *P < .05, Gli1 versus control. **P < .05 KCASH2 or KCASH3 + Gli1 versus Gli1. ***P <
.05 HDAC1 + Gli1 versus Gli1. ****P < .05 KCASH2 or KCASH3 + HDAC1 + Gli1 versus HDAC1 + Gli1. (F) KCASH3 function on Gli1
transcriptional activity requires the presence of endogenous KCASH1. Relative luciferase activity in HEK293T cells cotransfected with
12× Gli-Luc and pRL-TK Renilla plus Gli1, KCASH3 in the presence of siKCASH1 or siCTR. *P < .05, Gli1 + siCTR versus control. **P <
.05 KCASH3 + Gli1 + siCTR versus Gli1 + siCTR.
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Gli1K518R activity (Figure 5,D and E), thus suggesting that lysine 518
acetylation is required for their action. However, because KCASH3 was
unable to directly bind HDAC1, we hypothesized that its HDAC1-
dependentGli antagonism could require the cooperation of endogenous
KCASH1, which is able to recruit HDAC1 to the complex with Cul3
and KCASH3 as shown in Figure 4C . Indeed, siRNA-mediated de-
pletion of endogenous KCASH1 abrogated the inhibitory effect of
KCASH3 on Gli1-induced luciferase reporter activity (Figure 5F).
KCASH1, KCASH2, and KCASH3 Are Downregulated
in Human Primary MB
Given the role of KCASH2 and KCASH3 in regulation of Hh ac-
tivity, and the role of Hh in cerebellar tumorigenesis, we analyzed the
levels of KCASHs expression in a set of human sporadic MB sam-
ples. Indeed, both KCASH2 and KCASH3 showed a significant reduc-
tion of their expression levels in most tumors analyzed (Figures 6A and
W3A), suggesting that loss of both genes may contribute to MB.
Figure 6. Concerted KCASH1, KCASH2, and KCASH3 downregulated expression in human primary MBs and growth inhibitory role of
the KCASH family members. (A) Quantitative real-time PCR analysis of KCASH2, KCASH3 and KCASH1 expression in samples from
adult human cerebella (n = 9) and human primary medulloblastoma (n = 32). Data are means ± SD. **P = .0016, ***P = .0001 medullo-
blastoma versus adult human tissue. (B) Quantitative real-time PCR evaluation of KCASH1, KCASH2, and KCASH3 allelic copy number
(mean ± SD) in primary human MB (n, number of cases tested; B, blood). RNaseP was used as an endogenous control. (C, F) BrdU prolif-
eration assays: Daoy MB cells were transfected with indicated vectors, and percent of BrdU incorporating cells were measured to monitor
cell proliferation. *P< .05 versusempty vector (PCXN2). (D, G) Colony formation assay:Daoy cellswere transfectedwith the indicated vectors
and colony formation assay was performed to monitor cell proliferation. Representative images from experiments are shown. (E, H) Counts
from the colony formation assays are represented. *P < .05 KCASH2, KCASH3, and KCASH1 versus control vector. **P < .05 KCASH1 +
KCASH3 versus KCASH3 or KCASH1. Unless otherwise indicated, all experiments were performed in triplicate, and mean ± SD is shown.
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KCASH1 expression is also downregulated in the same MB samples
(Figure 6A), confirming the previously reported silencing on this gene
[34,35]. In fact, downregulated expression of KCASH1 has been re-
ported to be due both to promoter methylation [34,35] and to genetic
alteration because deletion of the 17p 13.1 chromosome region (where
this gene maps) occurs very frequently in human MB [34]. Interest-
ingly, human KCASH2 is located on chromosome 11q14.1, with
chromosome 11q loss being involved in several tumors including MB
[36,37]. The localization ofKCASH3 to the 3p14.3 chromosomal region
is also intriguing. Deletions and other rearrangements of this region have
been reported in a variety of tumor types, including malignant meso-
theliomas and carcinomas of the lung, kidney, breast, and ovary [38].
The existence of recurrent losses of chromosome 3p implicates the
involvement of a tumor suppressor gene in this region.
Therefore, we measured allelic loss of KCASH1, KCASH2, and
KCASH3 in genomic DNA from our MB samples. Although we did
not observe any loss of KCASH3 (hinting for a different epigenetic
silencing mechanism), we observed deletion of KCASH2 in 10%
of samples (Figure 6B), thus suggesting that genetic loss of this gene
is a relevant mechanism in MB formation. As expected, deletion of
KCASH1 was also present in 35% of samples (Figure 6B). Interestingly,
none of the MB analyzed presented deletion of both KCASH1 and
KCASH2 (not shown).
The observations presented here suggest that a reduced expression
of all three members of KCASH family may occur in MB, indicating
a contribution of the KCASH family in regulating proper develop-
ment and preventing Hh dysregulation leading to MB.
KCASH2 and KCASH3 Downregulate the Growth
of MB Cells
Hh signaling is critical for promoting the growth of MB cells [10].
The inhibitory role of KCASH2 and KCASH3 on Hh signaling and
their reduced expression in primary MB suggested that these proteins
could suppress tumor cell growth, similar to KCASH1 that displays
an antitumor activity [18,34]. Accordingly, KCASH2 and KCASH3
overexpression significantly reduced the growth of MB cell lines as
demonstrated by BrdU incorporation and colony formation assays (Fig-
ure 6, C–H ). In contrast, KCASH2 protein deleted of the Cul3 inter-
acting BTB domain (ΔBTB) did not suppress cell growth (Figure 6,
C–E ). Of note, we observed a cooperation between KCASH family
members in MB cell growth suppression as a general trait of the family.
In particular, the cooperative role of KCASH3 and KCASH1 was
indicated by the higher suppression of cell growth induced by com-
bined KCASH3 and KCASH1 overexpression compared with single
agents (Figure 6, F–H ).
Such a cooperative role was also confirmed as a more general trait of
the family by the observation of the higher suppression of tumor cell
growth induced by combined KCASH2 and KCASH1 (Figure W3,
B–C ). These results are in agreement with the inhibitory activity on
Gli1-induced Gli-reporter luciferase activity of coexpressed KCASH1
and -2 or KCASH1 and -3 proteins compared with overexpressed in-
dividual proteins (Figure W3, D and E).
Overall, our findings suggest that the above described Cul3-
dependent mechanism is involved in KCASH2 and KCASH3 tumor
growth suppressor function.
Discussion
We describe here two novel regulators of HDAC/Hh signaling and a
model by which the newly identified KCASH family of Cul3 ubiquitin
E3 ligase adaptors acts in concert to suppress HDAC1 and Hh/Gli
signaling (Figure 7). KCASH2 and KCASH3 share with KCASH1
(previously termed RENKCTD11) the ability to bind Cul3. By recruiting
Cul3 into a complex with HDAC1, KCASH2 promotes the ubiquiti-
nation and degradation of HDAC1, thereby inhibiting the previously
described deacetylation-mediated transcriptional activation of the Hh
effectors Gli1 and Gli2 [18]. In contrast, KCASH3, which is unable
to bind directly HDAC1, by exploiting its ability to heterodimerize
with KCASH1, recruits this deacetylase into a complex with Cul3, lead-
ing to HDAC1 ubiquitination and degradation as well as suppression
of Gli activity. Like KCASH1 [34], KCASH2 and KCASH3 expres-
sion was also significantly reduced in human MB. In addition to still
unidentified epigenetic silencing events, KCASH2 allelic deletion was
also observed to contribute to the reduced expression of this gene. Fi-
nally, rescuing the low expression of KCASH2 and KCASH3 reduces
the growth of Hh-dependent MB cells. This is of particular interest
because Hh/Gli signaling represents the master regulator of cerebellar
granule cell progenitor development (reviewed in Ruiz i Altaba [39])
as well as an oncogenic addiction pathway in MB [10,40]. These ob-
servations suggest that the increased expression of KCASH family
members in adult compared with fetal cerebellum and their genetic
and epigenetic downregulated expression in human MB may have an
in vivo relevance.
KCASH Family of HDAC1 Inhibitors Determine Concerted
Suppression of Hh Signaling
All three members of the KCASH family of Cul3 adaptors mediate
the suppression of HDAC1. However, the role of the three proteins is
not equal because KCASH3, while keeping the ability to bind Cul3,
does not bind directly HDAC1. Although KCASH3 may also target
other significant substrates to be still identified, it does indeed con-
trol HDAC1 by exploiting the ability of KCASH members to homo-
dimerize and heterodimerize. In particular, KCASH3 recruits HDAC1
into an active complex with Cul3 by binding KCASH1, which tether
HDAC1. Therefore, whereas the KCASH3/KCASH3 homodimer
does not have access to HDAC1 and is thus inactive, the KCASH3/
KCASH1 heterodimer is fully active on HDAC1 ubiquitination. These
findings suggest the presence of two functionally distinct classes of
KCASH family members: i) KCASH1 and 2, which are fully active
on HDAC1 also as homodimers; and ii) KCASH3, which requires
heterodimerization with the fully active KCASH1. Our observations
also suggest that KCASH family members act in cooperation to ubiqui-
tinate HDAC1 because their combination is functionally active and,
in certain conditions (KCASH3), is required. The different features
of these two classes of KCASH family members (inability of KCASH3
to interact with KCASH2 orHDAC1 and requirement for KCASH3 to
bind KCASH1 to recruit HDAC1 into the active Cul3 E3 ligase com-
plex) may reflect the divergence of these proteins during phylogenesis,
where KCASH3 earlier separates from both KCASH1 and 2, which
display more conserved functions.
Redundancy of KCASH-Mediated Regulation of HDAC1
and Hh in MB
The identification of the KCASH family adds new information to
the emerging mechanism of regulation of HDAC by inducing its
ubiquitin-dependent degradation (which is exploited also by Chfr
[25]). Whereas the targets regulated by the HDAC1/Chfr pathway have
not been specifically identified, the most interesting aspect of our
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observations is that the KCASH family control of HDAC1 results in
inhibition of the Hh signaling through the regulation of deacetylation-
dependent transcriptional activation of Gli1 (this study and that of
Canettieri et al. [18]).
The role of HDAC pharmacologic inhibition in the control of tumor
growth, the previously reported HDAC overexpression in cancer [17–
19], and the deletion or silencing of the HDAC-suppressor genes
observed in human tumors (reviewed in Di Marcotullio et al. [23]),
suggest their relevance as physiological mechanisms that, by repressing
HDAC function, prevent tumorigenesis.
Whereas HDACs comprise a heterogenous family with multiple
targets, suggesting redundancy of HDAC-dependent control of cell
functions involved in tumorigenesis, cancers are usually sustained by
specific oncogene addiction events representing the master tumorigenic
pathways [40]. Our findings suggest a redundant regulatory mecha-
nism occurring within the HDAC-dependent control of the unique
oncogenic addiction Hh/Gli pathway. Such a redundancy including
the contribution of the three members of the KCASH family implies
that they act in concert to optimally inhibit HDAC1 function and
the Hh pathway. This has been directly shown in this study by the
requirement of KCASH1 in the KCASH3-dependent regulation of
HDAC1/Hh pathway and by the cooperative activity of KCASH1
and KCASH2.
Furthermore, all KCASH family members are downregulated in
most human MB. Deletion of KCASH1 and 2 by 17p13.1 and
11q14.1 loss, respectively, contributes to their downregulated expres-
sion (this study and that of Di Marcotullio et al. [34]). Promoter
methylation of KCASH1 has also been reported to be responsible
for its downregulated expression in human MB [35]. Whether meth-
ylation is also contributing to the downregulated expression of KCASH2
and 3 remains to be elucidated. The combined downregulated ex-
pression of KCASH1, 2, and 3 in human MB suggests the requirement
of the misregulation of the mechanisms affecting such a redundant
KCASH-mediated control of HDAC1/Hh-Gli pathway in this tumor
(Figure 7).
In conclusion, the discovery of the above described KCASH family
members suggests that these negative regulators of Hh/Gli signaling
may act in concert as native HDAC inhibitors during development
and that their combined genetic or epigenetic defects are crucial in
sustaining Hh/Gli and HDAC-mediated tumorigenesis, proposing
their role as a promising class of endogenous “agents” by which this
oncogenic addiction pathways may be targeted.
Figure 7. The KCASH family acts in concert to suppress Hh/Gli signaling and tumorigenesis. We propose a model in which all members
of the KCASH family operate in concert, either as homo-oligomers or as hetero-oligomers to bind, ubiquitinate, and promote degradation
of HDAC1, thereby preserving Gli1 acetylation and suppressing Hh/Gli signaling (left side of the panel). Events that reduce the expres-
sion of KCASH members (genetically or epigenetically) allow the accumulation in the cell of HDAC protein and thus the deacetylation of
Gli1, which becomes fully transcriptionally active, driving the cells toward uncontrolled proliferation and eventually tumorigenesis (right
side of the panel).
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Figure W1. (A) Sequence alignment of human KCTD proteins. Matching amino acids are colored. The BTB domain is underlined on the
sequences. DFY is included in a black frame. A gene tree alignment of the three genes (with all the homolog from the different species) is
available in the Ensemble Web site at the following link: http://www.ensembl.org/Homo_sapiens/Gene/Compara_Tree?collapse=
1698431%2C1698526%2C1698557%2C1698502%2C1698474%2C1698581%2C1698491%2C1698481%2C1698496%2C1698492%
2C1698476;db=core;g=ENSG00000213859;r=17:7255208-7258258;t=ENST00000333751. (B) D283 cells transfected with siCTR and
siCASH2, in the presence or absence of Flag-tagged KCASH2, were immunoblotted with anti-KCASH2 and antiactin antibodies. Different
amounts of total lysates were analyzed to compare exogenous and endogenous signal (1:3 ratio, respectively). Unless otherwise indicated,
all experiments were performed in triplicate, and mean ± SD is shown.
Figure W2. (A) KCASH2 shows E3 ubiquitin ligase activity. HEK293T
cells, transfected with an HA-tagged KCASH2 or ΔBTB KCASH2
(ΔBTB) vectors, were treated with MG132 (50 μM) 6 hours before
lysis. Immunoprecipitation of cell lysates was carried out with an
anti-HA antibody, and immunocomplexeswere subjected to an in vitro
ubiquitination assay in the presence of Flag-ubiquitin (Flag-Ub) and
immunoblotted with an anti-Flag antibody to detect proteins ubiqui-
tinated by KCASH2. (B) KCASH2 and ΔBTB-KCASH2 levels in total
cell lysates.
Figure W3. (A) Expression levels of KCASH1-3 inMB samples. Expression levels are shown relative to the average value of normal cerebellum
(value set to 1). (B, C) Colony formation assay:Daoy cellswere transfectedwith indicated vectors. (B) Representative images fromexperiments
are shown. (C) Relative colony numbers are indicated. *P < .05 KCASH2 and KCASH1 versus control vector; **P < .05 KCASH1 + KCASH2
versus KCASH1 and KCASH2. Unless otherwise indicated, all experiments were performed in triplicate, andmean ± SD is shown. (D, E) Rela-
tive luciferase activity in HEK293T cells transfected with 12× Gli-Luc and pRL-TK Renilla and the indicated plasmids. Luciferase data are in-
dicated as mean ratios with respect to pRL-TK Renilla Luciferase control (Ctr). *P < .05 Gli1 versus control. **P < .05 KCASH1, KCASH2 or
KCASH3 + Gli1 versus Gli1. ***P < .05 KCASH2 + KCASH1 (or KCASH3 + KCASH1) + Gli1 versus KCASH1, -2, or -3 + Gli1.
